On February 3, 2023, the U.S. Food and Drug Administration approved sacituzumab govitecan-hziy for women 18 years or older with HR+/HER2-Metastatic Breast Cancer refractory to or relapsed after at least 2, and
By: Dr. Kanak Parmar On October 24, 2023 the U.S. Food and Drug Administration approved ivosidenib for adult patients with relapsed or refractory myelodysplastic syndromes (R/R MDS) with a susceptible isocitrate dehydrogenase-1
MoreBy Dr. Kanak Parmer Texas Tech University Health Sciences Center On October 16,2023 the U.S. Food and Drug Administration approved pembrolizumab for patients with resectable non-small cell lung cancer (NSCLC) tumors
MoreOn October 11, 2023, the U.S. Food and Drug Administration granted approval to Encorafenib (BRAF inhibitor) with Binimetinib (MEK inhibitor) for patients with metastatic non-small cell lung cancer (NSCLC) that was detected
MoreOn September 26, the U.S. Food and Drug Administration expanded the approval of bosutinib (Bosulif) to include pediatric patients 1 year of age and older. Previously, bosutinib had been approved for adults
MoreOn August 28, 2023, the U.S. Food and Drug Administration approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) without prior erythropoiesis-stimulating agent (ESA) use,
MoreBy Dr. Anish Shah Bronx-Lebanon Hospital On August 14, 2023, the U.S. Food and Drug Administration approved HEPZATO KIT – which is melphalan, as a liver-directed treatment for adult patients with
MoreBy Dr. Anish Shah Bronx-Lebanon Hospital On August 14, 2023, the U.S. Food and Drug Administration granted accelerated approval to Elranatamab-bcmm (Elrexfio) for adults with relapsed or refractory multiple myeloma who
MoreBy Dr. Anish Shah Bronx Lebanon Hospital On August 11, 2023, the U.S. Food and Drug Administration granted regular approval to niraparib and abiraterone acetate (Akeega) plus prednisone for adult patients
MoreBy Dr. Anish Shah Bronx Lebanon Hospital On August 9, 2023, the U.S. Food and Drug Administration approved talquetamab-tgvs (Talvey, Janssen Biotech, Inc.) for adults with multiple myeloma with relapsed or
MoreBy Dr. Anish Shah Bronx-Lebanon Hospital On August 9, 2023, the U.S. Food and Drug Administration granted regular approval to pralsetinib for adult patients with metastatic non-small cell lung cancer (NSCLC)
More